Mutations in microsomal triglyceride transfer protein (MTP) cause abetalipoproteinemia (ABL) characterized by the absence of plasma Apolipoprotein B (ApoB)-containing lipoproteins. In this study, we characterized the effects of various MTP missense mutations found in ABL patients with respect to their expression, subcellular location, and interaction with Protein Disulfide Isomerase (PDI). In addition, we characterized functional properties by analyzing phospholipid and triglyceride transfer activities and studied their ability to support apoB secretion. All the mutants co-localized with calnexin and interacted with PDI. We found that R540H and N780Y, known to be deficient in triglyceride transfer activity, also lacked phospholipid transfer activity. Novel mutants S590I and G746E did not transfer triglycerides and phospholipids and did not assist in apoB secretion. In contrast, D384A displayed both triglyceride and phospholipid transfer activities and supported apoB secretion. These studies point out that ABL is associated with the absence of both triglyceride and phospholipid transfer activities in MTP.
INTRODUCTION

Microsomal triglyceride transfer protein (MTP) is a heterodimer of a large ~97
kDa M subunit and a ~55 kDa Protein Disulfide Isomerase (PDI) P subunit held together by non-covalent interactions in 1:1 stoichiometry (1) (2) (3) (4) . PDI helps to maintain solubility and retention of MTP in the endoplasmic reticulum (1;2). The M-subunit of MTP is a single peptide of 894 amino acids. Based on its homology with lipovitellin, an ancient transport and storage lipoprotein found in egg laying vertebrates, MTP has been predicted to contain three major structural domains: N-terminal β-barrel (amino acids 22-297), central α-helical region (amino acids 298-603) and C-terminal domain (amino acids 604-894) (5) (6) (7) (8) . Based on mutagenesis followed by functional studies, it has been suggested that the N-terminal domain binds apoB (7), the central α-helical region interacts with both PDI and apoB (9) and the C-terminal domain is involved in lipid binding and transfer (7) . Bakillah et al. (10) identified small molecule inhibitors that differentially inhibit MTP's lipid transfer and apoB binding activities providing evidence for different by guest, on September 21, 2017 www.jlr.org Downloaded from functional domains. Further, it has been suggested that different domains of MTP carry out different functions (8;11) .
MTP facilitates transfer of lipids to nascent apoB while it is being cotranslationally translocated across the endoplasmic rticulum membrane thereby aiding in the assembly of primordial lipoprotein particles and preventing pre-secretory proteasomal degradation of apoB (12) . Kinetic studies predict that MTP has two lipid binding sites (13;14) ; the fast site is implicated in triglyceride and phospholipid transfer whereas the slow site in phospholipid transfer only. Evolutionary studies have suggested that MTP evolved as a phospholipid transfer protein and acquired triglyceride transfer during a transition from invertebrates to vertebrates (15) . Further, it was shown that phospholipid transfer activity of MTP is sufficient to support secretion of apolipoprotein B-containing lipoproteins in vitro and in vivo (16;17) .
Abetalipoproteinemia (ABL, OMIM#200100) is a rare autosomal recessive disorder due to mutations in the MTTP gene. Plasma triglycerides (< 0.23 mmol/L, 20 mg/dl) and cholesterol (< 1.16 mmol/L, 45 mg/dl) are typically low; in addition, LDL and apoB are undetectable. Acanthocytosis of red blood cells is a distinguishing feature on blood smears (18) . The severity of symptoms varies, and their subsequent downstream complications depend on early diagnosis and treatment. During the first and second decade, the first symptoms to be noticed are fat malabsorption, steatorrhea and failure to thrive. The other ramifications of the disease are fat-soluble vitamin deficiency, specifically vitamin E (19) and vitamin A, since apoB-containing lipoproteins distribute these vitamins to the peripheral tissues. Most prominent and debilitating clinical manifestations of ABL are neurological disorders caused by the deficiency of vitamin E and progressive degeneration of the central nervous system leading to death.
The majority of the mutations reported following sequence analysis of the MTP gene or cDNA in ABL subjects are frameshift, nonsense and splice site mutations that are predicted to encode truncated forms of MTP completely devoid of function (20) (21) (22) (23) (24) (25) (26) (27) (28) (23;30) , and G746E (25) have been described. Characterization of some of these mutants has provided significant information about the structure-function of MTP. Ricci et al. reported a nonsense mutation, G865X that caused loss of 30 amino acids at the Cterminal β-sheet of the 97 kDa MTP subunit (31) . The translated protein lost the ability to interact with PDI and was unable to transfer lipids indicating that C-terminal β-sheet may play a role in the formation of the active heterodimer. N780Y, located in the C-terminal end, has been shown to interact with PDI but lack triglyceride transfer activity (7;26) . It has been suggested to interact with membranes and extract lipids for transfer (7) . It does not support secretion of apoB41 but does support secretion of vitellogenin (32) . R540H neither transfers triglycerides nor supports apoB secretion (23) . It has been suggested to form an internal salt bridge to keep the central α-helical domain in proper conformation for PDI binding (6) . However, nothing is known about the ability of these two missense mutants to transfer phospholipids. ABL subjects homozygous for S590I have been reported (25) , but the biochemical reason for the disease phenotype has not been explained. In contrast, D384A and G746E have been reported as compound heterozygotes with other mutations and therefore it is not known whether these mutations affect MTP activity and contribute to the ABL phenotype (23;25;30) . In this study, we explored the effects of these missense mutations on various aspects of cellular, molecular and biochemical properties of MTP.
MATERIALS AND METHODS
Materials: 4-15% Ready Tris-HCl gels and precision-plus protein ladder were obtained from Bio-Rad Laboratories. ß-mercaptoethanol and restore western blot stripping buffer were purchased from Invitrogen and Thermo Scientific, respectively. Calcium chloride, ethylene diamine tetraacetic acid, Hepes, kanamycin, magnesium chloride, molecular weight markers, oleic acid, Tween-20 and Triton X-100 were bought from Sigma.
Glycerol, heparinized micro-hematocrit capillary tubes, sodium dodecyl sulfate, and sucrose were obtained from Fisher Chemicals. Fugene and lipofectamine were obtained from Roche and Invitrogen, respectively. Antibodies M2 FLAG, anti-human apoB, anti- were used to measure apoB by ELISA (34;35) . Cells were used to measure intracellular apoB. For this purpose, cells were scraped in cold PBS and a small sample was taken for total protein measurement. After centrifugation for 5 min at 100 g, pellets were lysed in cell extract buffer (100 mM Tris, pH 7.4, 150 mM NaCl, 1 mM EGTA, 1 mM EDTA,1%
Triton X-100, 0.5% Sodium deoxycholate) and rotated for 1 hour at 4 o C. The cell extract was centrifuged at 16,000 g, and the supernatant was used to measure apoB by ELISA (34) . Intracellular apoB was normalized to total cell protein.
Immunofluoroscence: Stable cell lines were grown on coverslips in 12-well cell culture plates, fixed, blocked and probed with primary and secondary antibodies as described earlier (16) . Cells were incubated with 0.05% Tween 20 in 10 mM sodium citrate buffer 
Lipid transfer assays:
Lipid transfer activities of MTP in COS7 cells stably expressing different mutants were determined by triglyceride and phospholipids transfer assays as described earlier (36;37). Cells were extensively washed in ice-cold PBS and homogenized in 1 ml of ice-cold homogenizing buffer (Tris-HCl, pH7.6; 1mM EGTA, and 1 mM MgCl2) containing protease inhibitor cocktail (Sigma) using a Dounce homogenizer. This low salt buffer is known to disrupt microsomes and release its contents (36) . Homogenates were centrifuged in a SW55 Ti rotor at 50,000 rpm for 1h at 
RESULTS
Structural illustration and location of missense mutations in MTP protein:
A diagram of the secondary structure of MTP based on PSIPRED secondary structure prediction (38) overlaid on the primary sequence shows N-and C-terminal β-sheets and a central α-helical domain ( Fig 1A) . Various ABL missense mutations have been identified to highlight their location in different regions of the protein (Fig 1A) . A schematic illustration of the secondary structure of MTP with respect to different predicted structural domains is shown in Fig 1B along with location of the mutations. A predicted tertiary structure build on lipovitellin (5;39) illustrates different structural domains and the location of different mutants (Fig 1C-D) . These analyses showed that mutations D384A, R540H and S590I are located in the central α-helical domain, whereas G746E
and N780Y are in the C-terminal β A sheet domain.
Expression of MTP mutants in stably transfected cells:
To study the importance of various amino acid residues, site-directed mutagenesis was employed to create individual missense mutations into the coding sequence of wildtype human MTP 97-kDa subunit.
These mutants were sequenced, cloned in the retrovirus expression vector pMFG-hMTP-FLAG, and stably expressed in COS7 cells that lack endogenous expression of apoB and MTP. Cells stably expressing pMFG-hMTP-FLAG were used as positive controls.
To determine whether single amino acid substitutions affect expression, we performed immunofluorescence using anti-FLAG antibodies. All mutant proteins could be detected in different cell lines (Fig 2) . In order to determine the subcellular location of these mutant proteins, cells were also stained for calnexin, an endoplasmic reticulum marker (Fig 2) . Merging of the calnexin and FLAG staining images showed overlap (yellow) suggesting their juxtaposition (Fig 2) . This expression pattern is consistent with those of human and Drosophila MTP reported earlier (16;17) . These data demonstrate that MTP mutants are expressed in these cells and localize similarly to hMTP in cells.
Heterodimerization of MTP mutants with PDI: MTP and PDI subunits form
heterodimers with a stoichiometry of 1:1 (2;3). This heterodimer formation is required to facilitate lipid transfer activity. Therefore, we performed immunofluorescence and coimmunoprecipitation analysis to study interactions between MTP and PDI subunits in COS7 cells stably expressing different MTP mutants (Fig 3) . Staining was seen for both MTP-FLAG and PDI in cells expressing hMTP and all other mutants. Overlap of MTP-FLAG and PDI was evident as yellow in merged images in most cell lines. In R540H expressing cells, there was less yellow color indicative of possibly sparse co-localization of these subunits (Fig 3) . Alternatively, this could be due to low intensity of the FLAG signal. These data indicate that, except for R540H, all mutant proteins are in close proximity of PDI in these cells.
We next determined whether MTP mutants co-immunoprecipitate with PDI.
FLAG proteins were immunoprecipitated using anti-FLAG M2 antibodies, and immunoprecipitated proteins were western blotted to detect MTP. Membranes were stripped and re-probed with anti-PDI antibodies (Fig 4) . No FLAG protein or PDI was detected in wildtype control cells indicating absence of proteins recognized by anti-FLAG antibodies in these cells. Immunoprecipitates obtained from COS7 cells expressing D384A, S590I, G746E and N780Y contained both FLAG and PDI ( Fig 4A) ; however, lower amounts of PDI were precipitated with R540H-FLAG consistent with
Mann et al. (6) . PDI/MTP ratios after the densitometric quantifications of bands are shown in Fig 4B. In most cases, this ratio ranged between 0.7-1, but was lower for R540H. These studies show that that all mutants, except for R540H, interact strongly with endogenous PDI. The reasons for low association of PDI with R540H are not known. It is likely that interactions between R540H and PDI are weaker than other MTP mutants.
Effect of missense mutations on distinct lipid transfer activities of MTP: First, we studied the expression of different mutants in duplicate cell cultures by measuring MTP mRNA levels ( Fig 5A) . All cell lines, except for D384A that showed higher mRNA levels, had similar levels of transcripts. To assay different lipid transfer activities, proteins were purified using anti-FLAG antibodies. Purification was necessary as we could not reliably measure phospholipid transfer activities neither in cell homogenates nor in microsomal lumenal contents. Western blot analysis showed that, except for the lower levels of G746E, we were able to purify different mutants and hMTP to similar extents ( Fig 5B) . Next, we examined triglyceride transfer activity in these purified proteins ( Fig 5C) . Significant triglyceride transfer activity was measurable in purified hMTP ( Fig 5C) . D384A exhibited significant triglyceride transfer activity, but it was lower than hMTP. In contrast, no triglyceride transfer activity was measurable in R540H, S590I, G746E and N780Y mutants. Besides triglyceride transfer, MTP also transfers phospholipids. Similar levels of phospholipid transfer activities were exhibited by hMTP and D384A. But no phospholipid transfer activity was measurable in R540H, S590I, G746E, and N780Y mutants (Fig 5D) . These studies show that R540H, S590I, G746E
and N780Y are deficient in both triglyceride and phospholipid transfer activities.
Ability of different missense mutations to support apoB lipoprotein assembly and secretion:
The major function of MTP is to support apoB lipoprotein assembly and secretion. To study apoB secretion, various cell lines stably expressing hMTP and different mutants were transiently transfected with apoB48-expressing plasmid. Different experiments were performed to measure intracellular apoB mRNA and protein levels. Fig 6A shows the mRNA levels of apoB in two different dishes of various cell lines (Fig 6A) .
All dishes had similar apoB mRNA levels except for one dish expressing N780Y. These studies indicated significant expression of apoB. We also measured MTP expression in different wells. Fig 6B shows the expression of different MTPs at the end of the experiment in two different wells. To study apoB secretion, we quantified media apoB.
ApoB was detectable in the media of cells stably expressing hMTP and D384A, but not in cells expressing R540H, S590I, G746E and N780Y (Fig 6C) . To eliminate the possibility that low availability of lipids affected apoB secretion, cells were supplemented with oleic acid complexed to BSA. ApoB secretion was enhanced by ~40% in cells expressing hMTP or D384A (Fig 6D) when compared with cells that were not supplemented with oleic acid (Fig 6C) . However, apoB was still not detectable in the media of cells expressing R540H, S590I, G746E and N780Y mutants. Consideration was given to the possibility that lack of apoB expression might be secondary to no cellular apoB protein. Cells were transfected with apoB48 expressing plasmids and intracellular apoB levels were quantified by ELISA (Fig 6E) . There were similar amounts of intracellular apoB in all cell lines indicating significant and equal expression. Thus, hMTP and D384 support apoB48 secretion, but other mutants do not.
DISCUSSION
Although it is established that MTP is indispensable for apoB lipoprotein assembly and secretion, gathering information about the structure and function of MTP has been hard due to difficulties in obtaining a three-dimensional X-ray crytallographic structure. Identification of missense mutations in the M subunit as the prime cause of ABL provided a possible new approach to explore structure-function relationships. We analyzed the effects of different reported ABL missense mutations on MTP function. Our studies confirm previous observations that R540H mutant neither transfers triglyceride nor supports apoB secretion while D384A does both (23) . Similarly, we also observed that N780Y interacts with PDI but does not transfer triglyceride as has been shown before (7;26) . Further our studies show that this missense mutation is incapable of supporting apoB48 secretion as has been reported for apoB41 (32) . We extend these studies to show that R540H and N780Y mutants also lack phospholipid transfer activity. Additionally, we report for the first time that S590I and G746E do not support apoB secretion. To identify mechanisms for their inability to support apoB secretion, we examined ER localization, interaction with PDI, and both triglyceride and phospholipid lipid transfer activities.
These mutants interacted with PDI, but were unable to transfer lipids. Thus, a proximal reason for ABL due to R540H, S590I, G746E and N780Y missense mutations might be the absence of both triglyceride and phospholipid transfer activities. S590I missense mutation was described in a 52 year subject with a lifelong history of fat malabsorption (29) and in a 24 year old subject (25) suggesting that this mutation might result in a milder ABL phenotype. Despite the milder clinical phenotype, these patients lacked plasma apoB-containing lipoproteins and showed acanthocytosis. It had been suggested that this mutation might not have a major impact on the synthesis and function of MTP (29) . Our in vitro studies, however, showed that MTP with this mutation has no lipid transfer activity and is unable to support assembly and secretion of apoB48-containing lipoproteins. Thus, this mutation has severe biochemical defects. These data explain the absence of apoB-containing lipoproteins in these patients, but do not provide any explanation regarding milder clinical phenotype especially with regards to the absence of neuropathy usually associated with vitamin E deficiency. It is possible that these subjects might have up-regulated an alternate mechanism of absorbing vitamin E independent of apoB-lipoproteins such as those involving transport via HDL despite having low levels (40;41).
S590 is located in the loop between helices 17 (amino acids 569-584) and 18
(amino acids 591-603) of the central α-helical region (Fig 7A) . It has been suggested (6) that residues I592, Y554, M555, and K558 (Fig 7B) are involved in PDI-binding as combined mutagenesis of Y554, M554, and I592 to alanine severely curtails PDI binding and triglyceride transfer activity. However, individual K591A, I592A, R594A, R595A, K598A, E599A (Fig 7C) substitutions had very small effects on MTP activity (6). Thus, it was surprising to see that S590I resulted in complete loss of MTP activity. It has been previously pointed out (6) that S590 could be part of a hydrophobic patch at the edge of the helical domain along with F585, M587, and A589 (Fig 7B) . S590I would increase hydrophobicity of the pocket. We noticed that S590 could also potentially form a hydrogen bond with M587 besides participating in the formation of a hydrophobic pocket between helices 17 and 18 (Fig 7B, 7C) . Further mutagenesis experiments are needed to resolve whether S590 is crucial because it contributes to an optimum hydrophobic pocket or its interaction with M587 is important for MTP activity.
G746E was reported as a compound heterozygote in an ABL subject (25) ; the other mutation found in this subject was a nonsense mutation resulting in the synthesis of a truncated protein. Therefore, it was not clear whether G746E contributes to the ABL phenotype. Our studies show that G746E missense mutation is accompanied with loss of triglyceride and phospholipid transfer activities in MTP and does not support apoB secretion. Thus, G746E alone could cause ABL. G746E is located in the deep pocket of MTP lipid transfer domain (Fig 7D) . We predict that introduction of a charged residue in this hydrophobic pocket might hinder neutral lipid acquisition for transfer. Thus, conversion of glycine to glutamic acid might create a hydrophilic environment untenable for the transfer of hydrophobic lipids.
Individuals homozygous for D384A have not been identified; instead this mutation has been presented as compound heterozygote with R540H (23). Therefore, physiologic effects of this mutation are unknown. We found that D384A has no significant impact on PDI binding, lipid transfer activities and apoB secretion consistent with other studies (23) . Hence, D384A is a polymorphism located in a highly conserved region of MTP and individuals homozygous for this mutation may not have significant phenotype. This is surprising since a mutation from D to A leading to loss of a negative charge is expected to cause significant structural changes. However, D384 is located between helices H5 (369-380) and H6 (386-398) of the central α-helical domain and is predicted to be surface accessible by Michael Sanner's Molecular Surface (MSMS)
analysis. Thus, a reason for no effect on MTP activity could be that due to its location on the surface of the molecule it is not critical for lipid transfer.
R540 is within the helix H15 (537-550) of the central α-helical domain and is not surface accessible. It has been suggested to form an internal salt bridge with E570 and N531 between helices 13 and 14 and the loop before the helix 16 (6) . The R540H mutation has been shown to reduce the association of the M subunit with the PDI subunit (6) . Further, it has been shown to lack triglyceride transfer activity and is unable to support apoB secretion (6;23). We also observed that R540H interacts poorly with PDI, is unable to transfer triglycerides and phospholipids and is incapable of assisting apoB secretion. These studies indicate that disruption of the internal salt bridge has a significant effect on MTP structure resulting in the loss of both the lipid transfer activities.
The C-terminal β-sheet of MTP has been suggested to be crucial for its lipid transfer activity. Within this C-sheet two α-helices, AH1 (residues 725-736) and AH2
(residues 781-786), have been proposed to play an important role in lipid transfer (7). This is based on the observation that N780Y missense mutation results in the loss of triglyceride transfer activity (7;26). We also observed that MTP carrying this mutation has very low triglyceride transfer activity and undetectable phospholipid transfer.
Apart from apoB-containing lipoprotein assembly in mammals, MTP is required for the secretion of vitellogenin A1 in frogs (32) . Vitellogenin is only secreted from COS cells when co-expressed with MTP. The secreted vitellogenin does not show flotation properties indicative of less neutral lipid association. Interestingly, N780Y missense mutation supports secretion of vitellogenin but not of apoB (32) . Since vitellogenin is secreted as a phospholipid-rich particle, we had hypothesized that N780Y might transfer phospholipids to aid in the secretion of vitellogenin. However, our studies showed that this missense mutant is also defective in phospholipid transfer activity. Therefore, MTP's chaperone activity that supports vitellogenin secretion is not related to its ability to transfer lipids. It has been shown that MTP interacts with vitellogenin (32) and this physical protein-protein interaction might be critical and sufficient for vitellogenin secretion.
In short, this study provides biochemical explanation for novel missense mutations, S590I and G746E, and expands the reasons for ABL in N780Y and R540H mutations. Apart from the absence of triglyceride transfer activity, our studies show that N780Y and R540H do not transfer phospholipids. We also found that S590I and G746E also lack both triglyceride and phospholipid transfer activities. Hence, these studies point out that ABL is associated with an inability to transfer both triglycerides and phospholipids.
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